Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine
Fawad A Khan, Steven P Herzog, Ryan M Smith, Dawn C Buse, Seema Soni-Brahmbhatt, Susanne F Awad, S Wald Grossman, Divya Asher, Foram Patel, Charles Argoff · 2025
Read Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine by Fawad A Khan, Steven P Herzog, Ryan M Smith, Dawn C Buse, Seema Soni-Brahmbhatt, Susanne F Awad, S Wald Grossman, Divya Asher, Foram Patel, Charles Argoff (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750955.txt.
Description
BackgroundData from the real-world REVIEW (Real-world EVidence and Insights into Experiences With eptinezumab) study demonstrated that, after starting treatment with eptinezumab, individuals with chronic migraine (CM) experienced double the number of good days per month and high rates of satisfaction with eptinezumab.
Catalog record
| CREATOR | Fawad A Khan, Steven P Herzog, Ryan M Smith, Dawn C Buse, Seema Soni-Brahmbhatt, Susanne F Awad, S Wald Grossman, Divya Asher, Foram Patel, Charles Argoff |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |